The Lancet Regional Health - Africa JANUARY 10, 2023

Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule

Ed Clarke, Isaac A. A. A., et al.

Bottom Line

This randomized, double-blind, active-controlled Phase 3 trial demonstrated that the 10-valent pneumococcal conjugate vaccine (Pneumosil) is safe and highly immunogenic when administered in a 2 + 1 schedule in infants.

Key Findings

1. Pneumosil (SIIPL-PCV) demonstrated robust immunogenicity, with post-booster serotype-specific IgG geometric mean concentrations (GMCs) ranging from 1.54 μg/mL (95% CI 1.38–1.73) for serotype 5 to 12.46 μg/mL (11.07–14.01) for serotype 6B.
2. Immune responses generated by Pneumosil were superior to the comparator PHiD-CV for seven of the eight shared serotypes (1, 5, 6B, 7F, 9V, 14, and 23F), while PHiD-CV showed a higher response for serotype 19F.
3. The safety profile was favorable, with no significant safety concerns or notable differences in adverse events compared to the licensed PCV comparators.
4. The vaccine showed no interference with the immunogenicity of other routine childhood immunizations when co-administered.

Study Design

Design
RCT
Double-Blind
Sample
660
Patients
Duration
4 weeks post-booster
Median
Setting
Single center, The Gambia
Population Healthy, PCV-naive infants aged 6–8 weeks
Intervention 10-valent pneumococcal conjugate vaccine (Pneumosil) administered in a 2 + 1 schedule
Comparator Licensed pneumococcal conjugate vaccines (PHiD-CV and PCV13)
Outcome Safety and immunogenicity (serotype-specific IgG GMCs and OPA titers)

Study Limitations

The study was conducted at a single center in The Gambia, which may limit the generalizability of findings to other epidemiological or geographical contexts.
While immunogenicity and safety were robust, the study was not powered or designed to evaluate clinical protection against invasive pneumococcal disease endpoints.
The study design utilized a specific 2 + 1 schedule, and findings may vary with different vaccination schedules used in other national programs.

Clinical Significance

Pneumosil provides a highly immunogenic and affordable alternative to existing pneumococcal conjugate vaccines for low- and middle-income countries, supporting its deployment in national immunization programs to reduce pneumococcal morbidity and mortality.

Historical Context

Developed by the Serum Institute of India (SIIPL) and PATH, Pneumosil was created to address the cost-prohibitive nature of previous PCVs. It received WHO prequalification in 2019, positioning it as a key tool for improving global vaccine access in Gavi-eligible nations.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What is the immunological rationale for conjugating pneumococcal polysaccharides to a protein carrier in vaccines like Pneumosil, and why is this particularly important for the infant population studied?

Key Response

Infants possess an immature immune system that does not respond effectively to T-cell independent antigens, such as pure bacterial polysaccharides. Conjugating these polysaccharides to a protein carrier (like CRM197) transforms the immune response into a T-cell dependent one. This induces the production of high-affinity antibodies and, crucially, establishes immunological memory (B-cells), which is essential for the long-term protection and the success of the booster dose in the 2 + 1 schedule.

Resident
Resident

When implementing a 2 + 1 schedule (at 6 weeks, 14 weeks, and 9 months) instead of a 3 + 0 schedule (6, 10, 14 weeks), what are the clinical trade-offs regarding early infant protection versus long-term herd immunity?

Key Response

The 3 + 0 schedule provides earlier completion of the primary series, offering maximum protection during the very early months of life when vulnerability to invasive pneumococcal disease (IPD) is high. However, the 2 + 1 schedule, as validated in this trial, typically results in higher antibody titers and better persistence after the booster dose at 9 months. This booster is critical for reducing nasopharyngeal carriage, which is the primary driver for herd immunity in the broader community.

Fellow
Fellow

Pneumosil covers 10 serotypes including 1, 5, and 7F. Discuss the clinical significance of these specific serotypes in the context of African epidemiology and how this vaccine compares to PCV13 regarding 'replacement serotypes' like 19A.

Key Response

Serotypes 1, 5, and 7F are major contributors to IPD outbreaks and high mortality in many African regions, making their inclusion in Pneumosil highly relevant. However, unlike PCV13, PCV10 formulations like Pneumosil do not include serotype 19A. Fellows must evaluate local surveillance data to determine if the cost-benefit of a more affordable 10-valent vaccine outweighs the potential risk of 19A-driven disease, which has seen an increase in some regions following the introduction of lower-valent PCVs.

Attending
Attending

Given that this trial used immunogenicity (IgG concentrations ≥0.35 µg/mL) as a non-inferiority endpoint, how should we counsel policy-makers on the real-world effectiveness of Pneumosil against non-bacteremic pneumonia compared to its efficacy against invasive disease?

Key Response

While the 0.35 µg/mL threshold is the WHO-recognized correlate of protection for invasive pneumococcal disease (IPD), it is widely accepted that higher antibody concentrations are likely required to prevent mucosal infections and non-bacteremic pneumonia. Practice-changing insight involves recognizing that 'non-inferiority' in antibody titers suggests similar IPD protection, but clinical effectiveness against the much larger burden of pneumonia requires ongoing post-marketing surveillance to ensure no loss of efficacy compared to more expensive predecessors.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

Critique the selection of the 10% non-inferiority margin and the use of the WHO aggregate correlate of protection (0.35 µg/mL) for a 10-valent vaccine where individual serotype performance may vary significantly.

Key Response

The 0.35 µg/mL threshold is a meta-analytical construct based on early PCV7 data and may not be the optimal correlate for all serotypes, especially 1 and 19F. A 10% margin is standard in many Phase 3 trials, but it may lack the sensitivity to detect clinically relevant differences in 'functional' immunity (Opsonophagocytic Activity, OPA). Methodologically, relying on GMC (Geometric Mean Concentration) can mask a wide distribution of responses, potentially leaving a subset of the population under-protected against specific high-virulence serotypes.

Journal Editor
Journal Editor

Does the use of an active control (Synflorix) in a non-inferiority design sufficiently address the safety profile of Pneumosil, or do the sample size limitations of this Phase 3 trial leave significant questions regarding rare but serious adverse events (SAEs)?

Key Response

While the trial demonstrates a comparable safety profile to an established PCV10, Phase 3 trials are generally underpowered to detect rare SAEs (occurring in <1/1000). Editors would flag that while 'safety is demonstrated' for common reactogenicity, the manuscript must emphasize the necessity of robust Phase 4 pharmacovigilance once the vaccine is deployed at scale in national immunization programs to truly confirm its safety profile.

Guideline Committee
Guideline Committee

Should the WHO SAGE recommendations be updated to place Pneumosil on equal footing with PCV13/15 for LMICs, and what specific evidence from this 2 + 1 trial supports that transition?

Key Response

Current WHO guidelines (2019) emphasize that PCV choice should be based on local serotype prevalence, vaccine supply, and cost. This trial provides Level 1 evidence that Pneumosil is non-inferior in a 2 + 1 schedule, which is often preferred for its boosting effect. If Pneumosil is significantly more affordable, the guideline committee may recommend it as a preferred option for LMICs to maximize coverage, provided local surveillance doesn't show a disproportionate burden of serotypes 3, 19A, or 22F (which are not in this PCV10).

Clinical Landscape

Noteworthy Related Trials

2009

PCV10 Phase 3 Clinical Trial

n = 2,467 · Lancet

Tested

10-valent pneumococcal conjugate vaccine (PHiD-CV)

Population

Healthy infants

Comparator

7-valent pneumococcal conjugate vaccine

Endpoint

Immunogenicity (antibody concentrations)

Key result: The PCV10 vaccine showed a non-inferior immunogenicity profile for all shared serotypes compared to the 7-valent vaccine.
2009

PHiD-CV Efficacy Trial

n = 24,000 · NEJM

Tested

10-valent pneumococcal conjugate vaccine (PHiD-CV)

Population

Infants in Finland

Comparator

Hepatitis B vaccine

Endpoint

Vaccine-type invasive pneumococcal disease

Key result: The trial demonstrated high vaccine efficacy against invasive pneumococcal disease caused by vaccine serotypes in infants.
2014

PCV10 3-dose schedule study in infants

n = 1,146 · Vaccine

Tested

10-valent pneumococcal conjugate vaccine

Population

Healthy infants

Comparator

PCV7 and pneumococcal polysaccharide vaccine

Endpoint

Serum IgG concentrations

Key result: A 3-dose schedule (2+1 or 3+0) induces robust immune responses against pneumococcal serotypes in infants.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis